-+ 0.00%
-+ 0.00%
-+ 0.00%
Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancer
Share
Listen to the news
Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancer
  • Natera filed Signatera with Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
  • The submission follows PMDA approval for Signatera in colorectal cancer in June.
  • Natera cited IMvigor011 Phase 3 trial data supporting the muscle-invasive bladder cancer filing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050600BIZWIRE_USPR_____20260805_BW954256) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending